Cardiac implantable electronic devices such as pacemakers, implantable cardioverter-defibrillators, and cardiac resynchronization therapy devices have transformed the management of arrhythmias and heart failure. However, a persistent challenge following implantation is the host tissue response, characterized by inflammation, fibrosis, and scarring around the device surface. This foreign body reaction can compromise device function, lead to lead failure, increase pacing thresholds, and necessitate surgical revision. Recent innovations in cardiac device surface engineering aim to minimize these adverse tissue responses, improving device integration, longevity, and patient outcomes. By modifying the physical and chemical properties of device surfaces, researchers are developing strategies that actively modulate the biological response from the moment of implantation.

The Biological Response to Cardiac Implants: Fibrosis and Scarring

When a foreign material is introduced into the body, the innate immune system initiates a cascade of events. Immediately after implantation, plasma proteins adsorb onto the device surface, forming a provisional matrix. This matrix triggers the recruitment and activation of neutrophils and macrophages, which attempt to engulf the device but are unable to do so due to its size. Persistent inflammation leads to macrophage fusion into foreign body giant cells, and subsequent release of pro-fibrotic cytokines such as transforming growth factor beta (TGF-β) and platelet-derived growth factor. These cytokines stimulate fibroblasts to proliferate and deposit dense collagenous extracellular matrix, resulting in a fibrous capsule surrounding the device.

In the context of cardiac devices, fibrosis occurs most critically at the electrode–tissue interface. Excessive fibrous tissue formation increases electrical impedance, reduces sensing amplitude, and elevates pacing thresholds. Over time, this can lead to exit block, failure to capture, or inappropriate shocks. Furthermore, extensive scarring can tether leads to the myocardium, increasing the risk of lead fracture or dislodgment. The fibrotic response also impairs the ability to extract leads when necessary, complicating device revisions or upgrades. Understanding the cellular and molecular mechanisms of fibrosis is essential for designing surface modifications that can disrupt or redirect these pathways.

Surface Engineering Strategies to Mitigate Fibrosis

Advanced surface engineering approaches aim to control protein adsorption, modulate immune cell behavior, and promote a healing response that minimizes capsule formation. These strategies can be broadly categorized into coatings, topographical modifications, and bioactive release systems. Below, we explore the most promising innovations currently under investigation.

Biocompatible Polymer Coatings

The simplest approach to reduce fibrosis is to apply a passive coating that resists protein adsorption and cell adhesion. Polyethylene glycol (PEG) is one of the most widely studied materials for this purpose. Its highly flexible, hydrophilic chains create a steric barrier that prevents proteins from binding to the underlying substrate. PEG-coated cardiac leads have demonstrated reduced inflammatory cell attachment and thinner fibrous capsules in animal models. However, PEG is susceptible to oxidative degradation in vivo, limiting long-term efficacy.

Zwitterionic polymers, such as poly(carboxybetaine) and poly(sulfobetaine), have emerged as more stable alternatives. Their equal numbers of positive and negative charges create an ultra-low fouling surface that resists protein adsorption even more effectively than PEG. Studies have shown that zwitterionic coatings on pacemaker leads significantly reduce macrophage adhesion and fibrous capsule thickness in subcutaneous implants. Another promising material is poly(2-methoxyethyl acrylate) (PMEA), which has been used in cardiovascular applications to suppress platelet activation and protein denaturation.

Hydrogels based on natural polymers like hyaluronic acid or alginate can also be applied as coatings. These materials mimic the native extracellular matrix and can be crosslinked to form a soft, hydrated layer that reduces mechanical mismatch between the device and tissue. Some hydrogels are designed to degrade slowly, releasing incorporated anti-inflammatory agents over time.

Drug-Eluting and Bioactive Coatings

Rather than relying solely on passive resistance, drug-eluting coatings actively suppress the inflammatory and fibrotic response. The concept is analogous to drug-eluting stents used in coronary arteries. For cardiac devices, anti-inflammatory drugs such as dexamethasone, sirolimus, and everolimus have been incorporated into polymer matrices or directly onto device surfaces. Dexamethasone, a corticosteroid, reduces the activation of macrophages and fibroblasts, thereby decreasing collagen deposition. Clinical studies have shown that steroid-eluting pacing leads achieve lower chronic pacing thresholds compared to non-eluting leads, confirming the utility of local drug delivery.

Beyond corticosteroids, researchers are exploring anti-fibrotic agents such as pirfenidone and tranilast, which inhibit TGF-β signaling pathways. Pirfenidone, approved for idiopathic pulmonary fibrosis, has been loaded into poly(lactic-co-glycolic acid) (PLGA) coatings on cardiac leads. In a rat model, pirfenidone-eluting leads reduced fibrous capsule thickness by approximately 50% at 12 weeks. Another strategy involves the release of nitric oxide (NO), a potent signaling molecule that inhibits platelet activation and smooth muscle proliferation. NO-releasing surfaces can be fabricated by incorporating NO donors, such as S-nitrosothiols, into polymer coatings. These coatings have shown promise in reducing both thrombosis and fibrosis in vascular implants.

Bioactive coatings can also include extracellular matrix components like laminin or fibronectin, which promote endothelialization and integration while minimizing inflammation. The challenge is to achieve selective cell adhesion—encouraging beneficial host cells (endothelial cells, cardiac myocytes) while discouraging immune cells and fibroblasts.

Nanotopographical Surface Modifications

Physical surface cues at the nanoscale can profoundly influence cell behavior. Cells sense and respond to topographical features such as grooves, ridges, pillars, and pores. By engineering these features onto cardiac device surfaces, researchers can direct cell morphology, alignment, and phenotype. For example, nanostructured titanium surfaces with features 50–200 nm in size have been shown to reduce fibroblast adhesion and spreading while promoting the attachment of cardiac fibroblasts in a more quiescent state.

Nanoporous surfaces created by anodization or etching can also reduce protein adsorption by limiting the available binding area. Additionally, aligned nanogrooves can guide the orientation of regenerating cardiac tissue, potentially improving the electrical interface. Some studies have used nano-imprinted polymer surfaces that mimic the natural architecture of the extracellular matrix, leading to reduced capsule formation compared to flat controls.

Another innovative approach is the use of carbon nanotubes or graphene derivatives. These materials can be patterned to create conductive, nano-textured surfaces that also improve signal transmission. However, concerns about the long-term biocompatibility and potential toxicity of carbon-based nanomaterials require careful evaluation before clinical translation.

Hydrophilic and Superhydrophilic Surfaces

Surface wettability is a key determinant of protein adsorption and cell attachment. Hydrophilic surfaces (water contact angle less than 90°) tend to adsorb less protein overall, while superhydrophilic surfaces (contact angle less than 10°) can form a stable water layer that repels proteins and cells. Plasma treatment, ultraviolet irradiation, or coating with titanium dioxide can render traditionally hydrophobic cardiac device materials (such as silicone or polyurethane) hydrophilic. In preclinical models, superhydrophilic silicone leads exhibited significantly reduced fibrous capsule thickness and lower macrophage density compared to untreated controls.

Conversely, deliberately hydrophobic surfaces have also been explored, but they tend to promote higher levels of protein adsorption and subsequent fibrosis. Thus, the current consensus favors hydrophilic or superhydrophilic modifications for cardiac implant surfaces.

Emerging Approaches: Biomimetic and Immunomodulatory Surfaces

The next generation of surface engineering aims to mimic the body's own tissues and actively regulate immune response. Biomimetic surfaces incorporate ligands that selectively bind to integrins on desired cell types. For example, RGD peptides (arginine-glycine-aspartate) promote adhesion of endothelial cells and myocytes, while PHSRN sequences can further enhance specificity. Coating cardiac leads with RGD-functionalized hydrogels has been shown to improve tissue integration and reduce inflammation in animal models.

Immunomodulatory surfaces go a step further by actively suppressing pro-inflammatory macrophage polarization and promoting a pro-healing M2 phenotype. One strategy is to immobilize interleukin-4 or interleukin-13 on the surface, which induces macrophage polarization toward the M2 state. Alternatively, surfaces that present CD47, a "don't eat me" signal, can prevent phagocytosis by macrophages and reduce foreign body giant cell formation. These approaches are still in early research stages but hold significant promise for creating truly bio-inert or bio-integrative devices.

Clinical Translation and Regulatory Considerations

Despite the impressive results achieved in preclinical studies, translating surface-engineered cardiac devices to the clinic remains a formidable challenge. Several factors must be addressed:

  • Long-term stability: Coatings must survive the mechanical stresses of implantation, sterilization, and in vivo degradation. Many polymers degrade or delaminate over months to years, potentially exposing the underlying substrate and negating the anti-fibrotic benefit.
  • Scalability and manufacturability: Techniques that work in the laboratory (e.g., electrospinning, chemical vapor deposition) may not be economically viable or reproducible at industrial scale. Manufacturers require robust, cost-effective processes that can be integrated into existing production lines.
  • Regulatory approval: New surface modifications are classified as class III medical devices or combination products (if they include a drug). The U.S. Food and Drug Administration (FDA) requires extensive biocompatibility testing per ISO 10993 standards, including cytotoxicity, sensitization, irritation, systemic toxicity, implantation, and carcinogenicity. Drug-eluting coatings may require additional clinical trials to demonstrate safety and efficacy.
  • Biocompatibility across patient demographics: Responses to surface treatments may vary based on age, sex, genetics, and underlying disease. A coating that works well in young healthy animals may induce excessive fibrosis in elderly patients with diabetes or heart failure.
  • Electrode function: Surface modifications must not adversely affect the electrical properties of pacing or defibrillation electrodes. Coatings must be thin and conductive enough to maintain low impedance and high charge injection capacity.

Several companies have successfully commercialized steroid-eluting leads (e.g., Medtronic's CapSureFix Novus, Abbott's Tendril STS), which remain the gold standard for reducing acute pacing thresholds. However, no purely surface-engineered technology has yet achieved widespread adoption for chronic fibrosis prevention. Ongoing collaborations between academic research groups and device manufacturers are essential to bridge the gap between benchtop innovation and clinical reality.

Future Directions in Cardiac Device Surface Engineering

The field is moving toward "smart" surfaces that can sense and respond to the local biological environment. For example, pH-responsive polymers that swell and release anti-inflammatory drugs in response to the acidic milieu of inflammation could provide on-demand therapy. Similarly, enzyme-responsive coatings that degrade and release payloads when MMPs (matrix metalloproteinases) are elevated could target the fibrotic process precisely.

Another exciting direction is the integration of microelectronics or microneedles into device surfaces. Microneedle arrays can deliver anti-fibrotic agents directly to the tissue interface with high spatial precision, bypassing systemic effects. These arrays could be combined with sensors to monitor local impedance or cytokine levels, enabling closed-loop control of drug release.

Personalized medicine approaches may also emerge, where a patient's own immune profile is used to select the optimal surface coating. For instance, patients with a known predisposition to excessive scarring (e.g., those with a history of keloids) might benefit from a more aggressive immunomodulatory coating, while others could be managed with a passive PEG coating. Machine learning algorithms could help predict fibrotic outcomes based on patient characteristics and guide implant selection.

Finally, fully bioresorbable or biodegradable cardiac devices are being explored. These devices would provide temporary pacing or defibrillation support while gradually dissolving, eliminating the need for extraction. The surface of such devices must be engineered to promote controlled degradation while minimizing inflammation during the absorption process. Early studies using biodegradable magnesium alloys coated with drug-eluting polymers have shown promise in animal models.

Conclusion

Surface engineering of cardiac devices represents a powerful strategy to combat fibrosis and scarring, which remain major obstacles to the long-term success of implanted electronics. Innovations such as zwitterionic polymers, drug-eluting coatings, nanotopographies, and immunomodulatory surfaces have demonstrated significant reductions in fibrous capsule formation in preclinical models. However, clinical translation demands robust manufacturing, prolonged stability, and thorough safety evaluation. As our understanding of the foreign body response deepens and new materials are developed, the next generation of cardiac implants will likely integrate multiple surface strategies—passive resistance, active drug release, and biomimetic cues—to achieve seamless integration with the host tissue. These advances promise to improve device performance, reduce complications, and enhance the quality of life for millions of patients worldwide.